ProtAffin AG strengthens Scientific Advisory Board with two new appointments

27-Aug-2007

ProtAffin AG, a biotechnology company developing anti-inflammatory therapeutics that act by targeting cell-surface glycan structures, announced that it has strengthened its Scientific Advisory Board by appointing two new members. Dr Timothy Wells and Dr Marco Sardinia are authorities in the fields of immunology and inflammation and they have extensive experience of drug development within pharmaceutical and biotechnology companies, which shall be beneficial to ProtAffin as its products move towards the clinic.

Dr Timothy Wells was previously Senior Executive Vice-President of R&D at Serono. There his responsibilities included drug innovation and development, taking programmes from target validation through pre-clinical development to completion of Phase I studies. He also managed Serono's R&D sites in Geneva, Boston, Paris, Ivrea (Italy), and Cambridge (UK). His research group in Geneva in the mid 90's focussed on cytokine immunology and identified several new chemokines and their receptors, and pioneered the application of these molecules in a wide range of diseases, from allergy through to HIV. Dr Wells has over 170 publications and several patent applications. Dr Wells has also published a number of papers on chemokines and their interactions with glycans, which is central to the mechanism of action of ProtAffin's anti-inflammatory products.

The second new member of ProtAffin's Scientific Advisory Board is Dr Marco Sardina MD, who is Medical Director, Strategic Development at Zambon Company. Zambon Company is an international pharmaceutical company headquartered in Milan, Italy that has a key focus on the commercialisation of anti-inflammatory, respiratory, and anti-infective products. Prior to his current role, Dr Sardina has worked at NicOx SA, Italfarmaco, Schering-Plough, Ciba-Geigy and Knoll in various positions. He has been involved in a number of pre-clinical, Phase I and Phase II programmes for anti-inflammatory, antihypertensive, antischemic, and antithrombotic products. He has particular experience in enabling the rapid entry of products into proof-of-concept and clinical studies.

https://www.bionity.com/en/news/68065/protaffin-ag-strengthens-scientific-advisory-board-with-two-new-appointments.html